Evaluating the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects

Zhaoke Ophthalmology

Status and phase: Unknown; Phase 2

Conditions: Corneal Defect

Treatments: Drug: ZKY001 eye drops 0.3g:0.012mg; Drug: ZKY001 eye drops 0.3g:0.006mg; Drug: ZKY001 simulated eye drops

Study type: Interventional

Funder types: Industry

Identifiers

NCT04228926

ZK-SFT-2019

Details and patient eligibility

About

The subjects of this study were patients who underwent corneal endothelial transplantation,who were randomly divided into 3 groups, 2 groups (0.002% and 0.004% ZKY001 eye drops) and 1 placebo control group.

Full description

This study is an exploratory phase II clinical study with no sample size estimation.According to the results of the preliminary animal experiments and phase I clinical trials, 2 concentrations (0.002% and 0.004%ZKY001eye drops) were selected as the experimental group, and 1 placebo control group was selected, with 35 subjects in each group and a total of 105 subjects.Each subject will drop the study drug into the test eye (the surgical eye is taken as the test eye) according to the randomly assigned drug number.

Enrollment: 105 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. age 18-80, regardless of gender;
2. patients who have undergone DSAEK or DMEK and need to remove corneal epithelium;
3. Schirmer test I ≥10mm/5min;
4. normal corneal limbus structure under slit lamp during screening period;
5. sign the informed consent.

Exclusion criteria

1. intraocular pressure > 21mmHg or baseline intraocular pressure > 35mmHg during screening period;
2. fasting blood glucose > 9.0mmol/L during screening period;
3. postoperative complications occurred, such as dislocation of the implant and high intraocular pressure caused by air bubbles in the anterior chamber;
4. suffered from eye infection, optic neuritis, pigment membrane inflammation, or fundus, macular lesions that affect vision, glaucoma;
5. serious cardiovascular history (congestive heart failure, uncontrolled hypertension, unstable coronary heart disease or myocardial infarction or severe arrhythmia, etc.);
6. severe hepatic and renal insufficiency, alanine aminotransferase (ALT), alanine aminotransferase (AST) ≥ 2 times the normal upper limit, blood creatinine (Cr) ≥ 1.5 times the normal upper limit;
7. those who wear contact lenses within 3 days before screening;
8. screening drugs that have used corneal repair effect within the first 3 days;
9. have received corneal refractive surgery or keratoplasty;
10. have received internal eye surgery within 3 months before screening or need to undergo internal eye surgery during the study period;
11. have participated in other clinical trials or are participating in other clinical trials within 3 months prior to screening;
12. suffering from central nervous system disease and/or mental state inability to cooperate;
13. women in pregnancy, lactation or childbearing age do not take effective contraceptive measures;
14. allergy to the test product and basic drugs;
15. patients who are not considered appropriate to participate in this study, including those who are unable or unwilling to comply with the protocol requirements.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

105 participants in 3 patient groups, including a placebo group

0.002% ZKY001 eye drops

Experimental group

Description:

Experimental group A: 35 subjects .0.002% ZKY001 eye drops . 4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).

Treatment:

Drug: ZKY001 eye drops 0.3g:0.006mg

0.004% ZKY001 eye drops

Experimental group

Description:

Experimental group B: 35 subjects .0.004% ZKY001 eye drops . 4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).

Treatment:

Drug: ZKY001 eye drops 0.3g:0.012mg

The placebo

Placebo Comparator group

Description:

Placebo group C: ZKY001 simulated eye drops .4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 simulated eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).

Treatment:

Drug: ZKY001 simulated eye drops